华东医药: 2023年度环境、社会和治理（ESG）报告（英文版）内容摘要

（原标题：2023年度环境、社会和治理（ESG）报告（英文版））

Huadong Medicine Co., Ltd. has released its 2023 Environmental, Social and Governance (ESG) Report (Stock Code 000963). The report covers the company's practices and performance in environmental protection, social responsibility, and corporate governance. Key points include:

• Achieved a 100% product pass rate, conducted 58 internal quality audits annually, and subjected 138 batches to market sampling inspections.
• Conducted a total of 424 risk assessments.
• Incurred zero product recall incidents, and no recalls were mandated by regulatory authorities.
• Implemented a comprehensive pharmacovigilance framework, including the Adverse Drug Reaction Reporting and Monitoring Procedures and the Internal Audit Management Process for Pharmacovigilance System.
• Regularly arranged specialized pharmacovigilance training sessions for pharmacovigilance officers and specialists.
• Improved the pharmacovigilance management system by introducing the Emergency Response Plan for Serious Adverse Drug Reactions and Mass Adverse Events.
• Established multiple channels for collecting drug safety information and managed individual safety reports using the eSafety pharmacovigilance system.
• Compiled stakeholder questionnaires for various groups, collecting a total of 426 responses.
• Hosted one "Investor Reception Day" event, conducted 108 online and on-site investor surveys, welcomed 2,393 investors, and engaged with investors 170 times on irm.cninfo.com.cn.
• Received awards such as the "Outstanding Practice Case of Listed Company Board Office in 2023" and the "Comein Award for Best IR Team of Value Delivery."
• Returned value to shareholders through various measures.